Laurus Labs Q1 FY27 Revenue Surges 29% to ₹2,026 Cr; Net Profit Jumps 126%
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Cr, up 29% YoY, and net profit of ₹368 Cr, up 126%. EBITDA rose 66% to ₹644 Cr with margins at 31.8%. CDMO revenue grew 67% to ₹870 Cr. The company in-licensed two ADCs and is investing in CAPEX for future growth.
The substantial year-on-year growth in revenue, profit, and EBITDA, coupled with strategic advancements in the CDMO and bio segments, indicates a significant positive impact on the company's financial health and future prospects.
The company reported record quarterly revenue, significant profit growth, and margin expansion, along with positive strategic developments like in-licensing new assets and progress on CAPEX plans.
Laurus Labs Limited announced its Unaudited Financial Results for the first quarter ended June 30, 2026 (Q1 FY27), reporting a record quarterly revenue of ₹2,026 crore, a significant increase of 29% compared to ₹1,570 crore in Q1 FY26. The company's net profit more than doubled, rising 126% to ₹368 crore from ₹163 crore in the prior year period. Diluted Earnings Per Share (EPS) also saw a substantial jump of 127% to ₹6.83 from ₹3.0.
The robust financial performance was driven by strong commercial deliveries within the Contract Development and Manufacturing Organization (CDMO) segment and continued strength in the Affordable Medicines portfolio. The CDMO business reported revenue of ₹870 crore, a 67% year-on-year increase, primarily fueled by growth in late-stage clinical and commercial API supplies. The Affordable Medicines division contributed ₹1,156 crore, a 10% increase, supported by steady ARV (Anti-Retroviral) revenue and growth in established products.
EBITDA for the quarter stood at ₹644 crore, a 66% increase from ₹389 crore in Q1 FY26, with EBITDA margins expanding by 7.0% to 31.8%. Gross margins improved by over 3 percentage points to 62.7%, attributed to a favorable business mix and improved capacity utilization. The company continued its investment in manufacturing network expansion and niche capabilities with capital expenditure (CAPEX) at 19% of sales, planned to support growth projects across various therapeutic areas.
Dr. Satyanarayana Chava, Founder & Chief Executive Officer, highlighted the company's portfolio transformation and strengthened integrated offerings. V. V. Ravi Kumar, Executive Director & Chief Financial Officer, emphasized the strong operating performance despite macroeconomic volatility and ongoing CAPEX programs to drive growth. Key strategic developments during the quarter included the in-licensing of two Antibody Drug Conjugates (ADCs) from Aarvik Therapeutics for development and commercialization in India. The company also reported progress on its fermentation facility commissioning, expected by Q3 FY27, and the KRKA JV FDF site, with Phase-I production blocks planned for mid-2027.
Laurus Labs also announced that its near-term science-based emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). The company will host an earnings conference call on Friday, July 24, 2026, at 5:00 pm IST to discuss the Q1 FY27 results.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.